Keyword: benralizumab

A lot has changed in the severe asthma market lately—including the way GlaxoSmithKline is talking about its contender, Nucala.

AZ struck out in May in trying to expand Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.

AstraZeneca's CEO knows he keeps saying the same thing, but once again, he had just one message for investors Thursday: Hang in there.

AstraZeneca's Fasenra hasn't had an easy time challenging GlaxoSmithKline’s Nucala. And doing so just got harder close to home.

AstraZeneca’s hopes for expanding severe asthma drug Fasenra into COPD are officially lost.

AZ was hoping its next-gen COPD med Fasenra could help it keep pace with GlaxoSmithKline, but the drug just failed to beat placebo in a phase 3 study.

Teva was hoping to level the convenience playing field in severe asthma with a subcutaneous version of Cinqair. But those plans have hit a snag.

GlaxoSmithKline may have some new Nucala competition in severe asthma, but it also has a new market all to itself.

GSK just inherited its biggest threat to Nucala in the form of a new AZ rival. But the British drugmaker says it’s down for some marketplace battling.

AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand out from a crowd that includes rivals GSK and Teva.